Cargando…

Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in Europe; however, it is important to understand how clinical practice patterns differ between countries and how this might relate to disease outcomes, to identify ways of improving local disease management....

Descripción completa

Detalles Bibliográficos
Autores principales: Whittaker, Hannah, Van Ganse, Eric, Dalon, Faustine, Nolin, Maeva, Marant-Micallef, Claire, Pison, Christophe, Ryan, Dermot P, Deslee, Gaetan, Quint, Jennifer K, Belhassen, Manon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367183/
https://www.ncbi.nlm.nih.gov/pubmed/35944943
http://dx.doi.org/10.1136/bmjresp-2021-001150
_version_ 1784765731304374272
author Whittaker, Hannah
Van Ganse, Eric
Dalon, Faustine
Nolin, Maeva
Marant-Micallef, Claire
Pison, Christophe
Ryan, Dermot P
Deslee, Gaetan
Quint, Jennifer K
Belhassen, Manon
author_facet Whittaker, Hannah
Van Ganse, Eric
Dalon, Faustine
Nolin, Maeva
Marant-Micallef, Claire
Pison, Christophe
Ryan, Dermot P
Deslee, Gaetan
Quint, Jennifer K
Belhassen, Manon
author_sort Whittaker, Hannah
collection PubMed
description INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in Europe; however, it is important to understand how clinical practice patterns differ between countries and how this might relate to disease outcomes, to identify ways of improving local disease management. We aimed to describe and compare the management of patients with COPD in the UK and France between 2008 and 2017. METHODS: We used data from the Clinical Practice Research Datalink GOLD and Hospital Episode Statistics in the UK and the Echantillon Généraliste des Bénéficiaire in France to identify patients with COPD each year between 2008 and 2017. We compared patient characteristics, all-cause mortality and COPD exacerbations each year between 2008 and 2017 for patients in the UK and France separately. Health care utilisation and COPD exacerbations in 2017 were compared between France and the UK using t-tests and χ(2) tests. RESULTS: Patients with COPD were similar in gender and comorbidities in both countries. Incidence of COPD exacerbations remained stable in the UK and France between 2007 and 2017. In 2017, the proportion of all-cause and COPD-related hospitalisations was greater in the UK than in France (43.9% vs 32.8% and 8.3% vs 4.9%, respectively; p<0.001) as was the proportion of patients visiting accident and emergency (A&E) (39.8% vs 16.2%, respectively; p<0.001). In addition, the mean length of stay in hospital for COPD-related causes was shorter in the UK than in France (6.2 days (SD 8.4) vs 10.5 days (SD 9.1), respectively; p<0.001). DISCUSSION: Overall, UK patients were more likely to go to A&E, be hospitalised for COPD-related causes and stay in hospital for fewer days after being admitted for COPD-related reasons compared with patients in France, illustrating a difference in health-seeking behaviours and access to healthcare.
format Online
Article
Text
id pubmed-9367183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-93671832022-08-22 Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France Whittaker, Hannah Van Ganse, Eric Dalon, Faustine Nolin, Maeva Marant-Micallef, Claire Pison, Christophe Ryan, Dermot P Deslee, Gaetan Quint, Jennifer K Belhassen, Manon BMJ Open Respir Res Chronic Obstructive Pulmonary Disease INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in Europe; however, it is important to understand how clinical practice patterns differ between countries and how this might relate to disease outcomes, to identify ways of improving local disease management. We aimed to describe and compare the management of patients with COPD in the UK and France between 2008 and 2017. METHODS: We used data from the Clinical Practice Research Datalink GOLD and Hospital Episode Statistics in the UK and the Echantillon Généraliste des Bénéficiaire in France to identify patients with COPD each year between 2008 and 2017. We compared patient characteristics, all-cause mortality and COPD exacerbations each year between 2008 and 2017 for patients in the UK and France separately. Health care utilisation and COPD exacerbations in 2017 were compared between France and the UK using t-tests and χ(2) tests. RESULTS: Patients with COPD were similar in gender and comorbidities in both countries. Incidence of COPD exacerbations remained stable in the UK and France between 2007 and 2017. In 2017, the proportion of all-cause and COPD-related hospitalisations was greater in the UK than in France (43.9% vs 32.8% and 8.3% vs 4.9%, respectively; p<0.001) as was the proportion of patients visiting accident and emergency (A&E) (39.8% vs 16.2%, respectively; p<0.001). In addition, the mean length of stay in hospital for COPD-related causes was shorter in the UK than in France (6.2 days (SD 8.4) vs 10.5 days (SD 9.1), respectively; p<0.001). DISCUSSION: Overall, UK patients were more likely to go to A&E, be hospitalised for COPD-related causes and stay in hospital for fewer days after being admitted for COPD-related reasons compared with patients in France, illustrating a difference in health-seeking behaviours and access to healthcare. BMJ Publishing Group 2022-08-09 /pmc/articles/PMC9367183/ /pubmed/35944943 http://dx.doi.org/10.1136/bmjresp-2021-001150 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Chronic Obstructive Pulmonary Disease
Whittaker, Hannah
Van Ganse, Eric
Dalon, Faustine
Nolin, Maeva
Marant-Micallef, Claire
Pison, Christophe
Ryan, Dermot P
Deslee, Gaetan
Quint, Jennifer K
Belhassen, Manon
Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
title Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
title_full Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
title_fullStr Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
title_full_unstemmed Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
title_short Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
title_sort differences in severe exacerbations rates and healthcare utilisation in copd populations in the uk and france
topic Chronic Obstructive Pulmonary Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367183/
https://www.ncbi.nlm.nih.gov/pubmed/35944943
http://dx.doi.org/10.1136/bmjresp-2021-001150
work_keys_str_mv AT whittakerhannah differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT vanganseeric differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT dalonfaustine differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT nolinmaeva differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT marantmicallefclaire differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT pisonchristophe differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT ryandermotp differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT desleegaetan differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT quintjenniferk differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance
AT belhassenmanon differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance